Clinical trials: No Eye Disorder
no Obvious Abnormalities, Diabetic Retinopathy (DR)
Retinal Clinical Assessment With AI-derived Quantitative Information
This randomized controlled trial evaluates whether providing clinicians with AI-derived quantitative retinal information improves the quality and efficiency of retinal clinical assessment.
- Conditions
- no Obvious Abnormalities, Diabetic Retinopathy (DR), AMD, Cup-to-disc Ratio Bigger Than 0.5
- Trial name
- NCT07291960
- Testing
- AI-derived retinal quantitative information-assisted reporting
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Beijing Tongren Hospital
Retinopathy of Prematurity
Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1
The Retinopathy of Prematurity (ROP) is a Retina's pathology only of the premature baby, it's characterized for proliferation of vascular tissue that grow in the limit between the vascular retina and the avascular retina.
- Trial name
- Bevacizumab (NCT02090322)
- Testing
- Injection of bevacizumab intravitreal (Avastin)
- Where
- 3 sites in Mexico
- Volunteers
- 60 people
- Sponsor
- Universidad Autonoma de San Luis Potosí
Myopia
Assessment of the Efficacy and Safety of a DYnaMic Peripheral DegradatiON Myopia Disorder Control in Myopic Children ״DYMOND Study״
The DYMOND study evaluates the safety and effectiveness of TrackSight™, a digital medical application designed to slow myopia (nearsightedness) progression in children during everyday screen use.
- Trial name
- DYMOND (NCT07390500)
- Testing
- TrackSight
- Where
- Israel
- Volunteers
- 150 people
- Sponsor
- NovaSight
Cataract With Exfoliation Syndrome
Efficacy of a Capsular Tension Ring in Preventing Anterior Capsule Shrinkage After Cataract Surgery in Exfoliation Syndrome
The purpose of this study is to examine the efficacy of a capsular tension ring (CTR) in preventing anterior capsule shrinkage after cataract surgery in exfoliation syndrome (XFS) with no zonular weakness.
- Trial name
- Effect of CTR (NCT01455168)
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- University of Occupational and Environmental Health
Junctional Epidermolysis Bullosa, Epidermolysis Bullosa (EB)
Pilot Study of ELK-003 Eye Drops for Treating Ocular Manifestations of Epidermolysis Bullosa
This study consists of two phases: an Observational Phase to evaluate the natural history of ocular manifestations in subjects with Dystrophic and Junctional Epidermolysis Bullosa, followed by a Treatment Phase to assess the…
- Conditions
- Junctional Epidermolysis Bullosa, Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
- Trial name
- GOTAS-ELK-EB (NCT06713434)
- Testing
- ELK-003 (Standarized Amniotic Fluid Secretome Eye Drops)
- Where
- Chile
- Volunteers
- 20 people
- Sponsor
- Fundación DEBRA Chile, Niños Piel de Cristal
Clubfoot
Comparison of Surgical Blade No. 11 and Ophthalmic Knife in Idiopathic Clubfoot Patients
There is limited local data available on the comparison between surgical blade no.11 and ophthalmic knife among patients with neglected clubfoot going through tenotomy.
- Trial name
- NCT07561736
- Testing
- Surgical Blade, Ophthalmic Knife
- Where
- Pakistan
- Volunteers
- 102 people
- Sponsor
- Muhammad Aamir Latif
Retinoblastoma
Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye
RATIONALE: Drugs used in chemotherapy, such as carboplatin, vincristine, etoposide, and cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00360750
- Testing
- carboplatin, cytarabine, etoposide
- Where
- 13 sites in United Kingdom
- Sponsor
- Children's Cancer and Leukaemia Group
Rhinitis Allergic, Conjunctivitis
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
This is a study to evaluate the efficacy and safety of grass sublingual tablet (SCH 697243) versus placebo in the treatment of grass pollen-induced allergic hayfever symptoms.
- Trial name
- NCT01385371
- Testing
- Grass (Phleum pratense) pollen allergen extract
- Volunteers
- 1,501 people
- Sponsor
- ALK-Abelló A/S